Cover Image
Market Research Report

Global Diabetic Retinopathy Market 2018-2025

Published by DataM Intelligence Product code 787281
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Diabetic Retinopathy Market 2018-2025
Published: November 1, 2018 Content info: 130-180 Pages
Description

DIABETIC RETINOPATHY MARKET

Diabetic retinopathy (DR) is a highly specific neurovascular complication of both type 1 and type 2 diabetes.

It occurs when changes in blood glucose levels cause retinal blood vessel changes.

DR is a leading cause of vision loss globally.

The Global Diabetic Retinopathy market is estimated to reach USD 2.5 billion by 2022.

MARKET GROWTH AND TRENDS

Increasing prevalence of diabetes is the prime factor driving growth of Diabetic Retinopathy market.

Globally, an estimated 422 million adults are living with diabetes. In addition, rising patient awareness levels and increasing healthcare expenditure will fuel market growth.

However, lack of skilled professionals, extended approval time for drugs in conjunction with the strict regulatory requirements will restrict market growth.

MARKET SEGMENTATION

Global Diabetic Retinopathy market report segments the market by indication type, by treatment type, by end user and by region.

Based on stages of diabetic retinopathy, the market is segmented into Non-proliferative diabetic retinopathy (NPDR) and Proliferative diabetic retinopathy (PDR).

Proliferative diabetic retinopathy segment is the most common form of diabetic retinopathy, accounting for approximately 80% of all cases.

Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific and RoW.

North America will dominate the market owing to high prevalence of diabetes, high awareness among people about diabetic retinopathy, availability of treatment options and better reimbursement policies.

SCOPE OF THE REPORT

The report also profiles the following companies of Diabetic Retinopathy market - Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche, Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., and Valeant Pharmaceutical.

BY INDICATION TYPE

Non-Proliferative Diabetic Retinopathy (NPDR)

Proliferative Diabetic Retinopathy (PDR)

BY TREATMENT TYPE

Anti-Vascular Endothelial Growth Factor (VEGF) drug

Intraocular Steroid Injection

Laser Surgery

Vitrectomy

BY END USER

Hospitals

Ophthalmic Clinics

Ambulatory Surgical Centers

BY REGION

Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

North America (The USA, Canada, Mexico)

South America (Brazil, Argentina, Rest of South America)

Rest of the World

WHY PURCHASE THE REPORT?

Visualize the composition of Diabetic Retinopathy market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.

Identify commercial opportunities in Diabetic Retinopathy market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for key products of all major market players

TARGET AUDIENCE

Equipment Suppliers/ Buyers

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

Table of Contents

CHAPTER 1 METHODOLOGY AND SCOPE

  • 1.1 Research Methodology
  • 1.2 Scope of the Report

CHAPTER 2- GLOBAL DIABETIC RETINOPATHY MARKET - TRENDS

  • 2.1 Key Trends & Developments

CHAPTER 3 -GLOBAL DIABETIC RETINOPATHY MARKET - INDUSTRY ANALYSIS

Market Drivers

Increasing prevalence of diabetes

Rising patient awareness

Increasing healthcare expenditure

Market Restraints

Lack of skilled professionals

Extended drug approval time

Threats and Opportunities

Porter's 5 Forces

CHAPTER 4-GLOBAL DIABETIC RETINOPATHY MARKET - MARKET ANALYSIS

Diabetic Retinopathy Market- By Indication Type

Non-Proliferative Diabetic Retinopathy (NPDR)

Proliferative Diabetic Retinopathy (PDR)

Diabetic Retinopathy Market - By Treatment Type

Anti-Vascular Endothelial Growth Factor (VEGF) drug

Intraocular Steroid Injection

Laser Surgery

Vitrectomy

Diabetic Retinopathy Market - By End User

Hospitals

Ophthalmic Clinics

Ambulatory Surgical Centres

CHAPTER 5- GLOBAL DIABETIC RETINOPATHY MARKET - GEOGRAPHICAL ANALYSIS

  • 5.1. North America
    • 5.1.1. The USA
    • 5.1.2. Canada
    • 5.1.3. Mexico
  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. The UK
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. Rest of Europe
  • 5.3. Asia Pacific
    • 5.3.1. China
    • 5.3.2. Japan
    • 5.3.3. India
    • 5.3.4. Australia
    • 5.3.5. Rest of Asia Pacific
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5 Rest of the World

CHAPTER 6 -GLOBAL DIABETIC RETINOPATHY MARKET - COMPETITIVE LANDSCAPE

  • 6.1. Market Share Analysis
  • 6.2. Mergers and Acquisitions Analysis
  • 6.3. New Product Launches

CHAPTER 7- GLOBAL DIABETIC RETINOPATHY MARKET - COMPANY PROFILES

Abbott Laboratories

Alimera Science

Allergan plc

Ampio Pharmaceuticals.

Bayer AG

Hoffmann-La Roche

Novartis International AG

Pfizer

Regeneron Pharmaceuticals Inc.

Valeant Pharmaceutical

CHAPTER 8 -GLOBAL DIABETIC RETINOPATHY MARKET - APPENDIX

  • 8.1 Sources
  • 8.2 List of Tables
  • 8.3 Expert Panel Validation
  • 8.4 Disclaimer
  • 8.5 Contact Us
Back to Top